Effect of pre- and post-treatment α-fetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: A retrospective study

BMC Surgery

Volumn 14, Issue 1, 2014, Pages

  Toro, Adriana ^a   Ardiri, Annalisa ^a   Mannino, Maurizio ^a   Arcerito, Maria Concetta ^a   Mannino, Giovanni ^b   Palermo, Filippo ^a   Bertino, Gaetano ^a   Di Carlo, Isidoro ^a,c  

^a UNIVERSITY OF CATANIA   (Italy)

^b CANNIZZARO HOSPITAL   (Italy)

^c HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

Alpha fetoprotein; Hepatic resection; Hepatocellular carcinoma; Radiofrequency ablation; Survival; Transarterial chemoembolization; Tumor size

Indexed keywords

ALPHA FETOPROTEIN; TUMOR MARKER;

ADULT; AGED; BLOOD; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION; EPIDEMIOLOGY; FEMALE; FOLLOW UP; HUMAN; ITALY; LIVER NEOPLASMS; LIVER RESECTION; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TRENDS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; ITALY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84905560438     PISSN: None     EISSN: 14712482     Source Type: Journal    
DOI: 10.1186/1471-2482-14-40     Document Type: Article

References (35)

1. Epidemiology of hepatocellular carcinoma in USA. El-Serag HB, Hepatol Res 2007 37 Suppl 2 88 S94
2. The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. Arrieta O, Cacho B, Morales-Espinosa D, Ruelas-Villavicencio A, Flores-Estrada D, Hernandez-Pedro N, BMC Cancer 2007 8 28
3. Risk factors for early recurrence of small hepatocellular carcinoma after curative resection. Zhou YM, Yang JM, Li B, Yin ZF, Xu F, Wang B, Xu W, Kan T, Hepatobiliary Pancreas Dis Int 2010 9 33 37
4. Two patients with extremely elevated tumor markers: where is the malignancy? Van der Veek PP, de Vos Tot Nederveen Cappel WH, Langers AM, van Hoek B, Gastroenterol Res Pract 2011 2011 123743 doi:10.1155/2011/123743. Epub 2011 Jun 16
5. Practice Guidelines Committee, American Association for the Study of Liver Diseases Management of hepatocellular carcinoma. Bruix J, Sherman M, Hepatology 2005 42 1208 1236
6. Reference change value for alpha-fetoprotein and its application in early detection of hepatocellular carcinoma in patients with hepatic disease. Trapé J, Botargues JM, Porta F, Ricós C, Badal JM, Salinas R, Sala M, Roca A, Clin Chem 2003 49 1209 1211 (Pubitemid 36751118)
7. Prognostic features and survival of hepatocellular carcinoma in Italy: impact of stage of disease. Lerose R, Molinari R, Rocchi E, Manenti F, Villa E, Eur J Cancer 2001 37 239 245 (Pubitemid 32144702)
8. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Christensen E, Schlichting P, Fauerholdt L, Gluud C, Andersen PK, Juhl E, Poulsen H, Tygstrup N, Hepatology 1984 4 430 435 (Pubitemid 14116643)
9. Hepatocellular carcinoma in Italian patients with cirrhosis. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, Donato MF, Piva A, Di Carlo V, Dioguardi N, N Engl J Med 1991 325 675 680
10. Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Zaman SN, Melia WM, Johnson RD, Portmann BC, Johnson PJ, Williams R, Lancet 1985 1 1357 1360 (Pubitemid 15060907)
11. Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment, monitoring or both? Chan SL, Chan AT, Yeo W, Future Oncol 2009 5 889 899
12. Criteria for safe hepatic resection. Miyagawa S, Makuuchi M, Kawasaki S, Kakazu T, Am J Surg 1995 169 589 594
13. Terminology of liver anatomy and resections. Terminology Committee of the IHPBA, HPB Surg 2000 2 333 339
14. Current status of therapy for hepatocellular carcinoma. Corey KE, Pratts DS, Therap Adv Gastroenterol 2009 2 45 57
15. Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma. Li P, Wang SS, Liu H, Li N, McNutt MA, Li G, Ding HG, World J Gastroenterol 2011 17 4563 4571
16. Corelation of serum alpha fetoprotein and tumor size in hepatocellular carcinoma. Abbasi A, Bhutto AR, Butt N, Munir SM, J Pak Med Assoc 2012 62 33 36
17. Survival rates according to the Cancer of the Liver Italian Program scores of 345 hepatocellular carcinoma patients after multimodality treatments during a 10-year period in a retrospective study. Yamagiwa K, Shiraki K, Yamakado K, Mizuno S, Hori T, Yagi S, Hamada T, Iida T, Nakamura I, Fujii K, Usui M, Isaji S, Ito K, Tagawa S, Takeda K, Yokoi H, Noguchi T, J Gastroenterol Hepatol 2008 23 482 490 (Pubitemid 351342072)
18. Alpha-fetoprotein enhances the proliferation of human hepatoma cells in vitro. Wang XW, Xie H, Life Sci 1999 64 17 23 (Pubitemid 29012745)
19. The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel7402 cell line. Li MS, Li PF, He SP, Du GG, Li G, World J Gastroenterol 2002 8 469 475 (Pubitemid 34692744)
20. Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel 7402 cells. Li MS, Li PF, Chen Q, Du GG, Li G, World J Gastroenterol 2004 10 819 824 (Pubitemid 38418353)
21. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma. Fujioka M, Nakashima Y, Nakashima O, Kojiro M, Hepatology 2001 34 1128 1134 (Pubitemid 33096585)
22. Silencing alphafetoprotein expression induces growth arrest and apoptosis in human hepatocellular cancer cell. Yang X, Zhang Y, Zhang L, Zhang L, Mao J, Cancer Lett 2008 271 281 293
23. Targeting alpha-fetoprotein represses the proliferation of hepatoma cells via regulation of the cell cycle. Tang H, Tang XY, Liu M, Li X, Clin Chim Acta 2008 394 81 88
24. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Shimada M, Takenaka K, Gion T, Fujiwara Y, Kajiyama K, Maeda T, Shirabe K, Nishizaki T, Yanaga K, Sugimachi K, Gastroenterology 1996 111 720 726 (Pubitemid 26293238)
25. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J, Cancer 2000 89 500 507 (Pubitemid 30640096)
26. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Tung-Ping Poon R, Fan ST, Wong J, Ann Surg 2000 232 10 24 (Pubitemid 30456545)
27. Factors correlated with portal venous invasion by hepatocellular carcinoma: univariate and multivariate analyses of 232 resected cases without preoperative treatments. Adachi E, Maeda T, Kajiyama K, Kinukawa N, Matsumata T, Sugimachi K, Tsuneyoshi M, Cancer 1996 77 2022 2031 (Pubitemid 26142044)
28. Hepatocellular carcinoma: natural history, current management, and emerging tools. Tinkle CL, Haas-Kogan D, Biologics 2012 6 207 219
29. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, Okita K, Omata M, Takayasu K, Yamaoka Y, Cancer 2004 101 796 802 (Pubitemid 39030937)
30. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, Ibrahim SM, Sato KT, Baker T, Miller FH, Newman S, Omary R, Abecassis M, Benson AB 3rd, Salem R, J Clin Oncol 2009 27 5734 5742
31. Transarterial chemoembolization for hepatocellular carcinoma: significance of extrahepatic collateral supply. Sawhney S, Montano-Loza AJ, Salat P, McCarthy M, Kneteman N, Meza-Junco J, Owen R, Can J Gastroenterol 2011 25 426 432
32. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. Harrison LE, Koneru B, Baramipour P, Fisher A, Barone A, Wilson D, Dela Torre A, Cho KC, Contractor D, Korogodsky M, J Am Coll Surg 2003 197 759 764 (Pubitemid 38199577)
33. Risk factors for the local recurrence of hepatocellular carcinoma after a single session of percutaneous radiofrequency ablation. Hori T, Nagata K, Hasuike S, Onaga M, Motoda M, Moriuchi A, Iwakiri H, Uto H, Kato J, Ido A, Hayashi K, Tsubouchi H, J Gastroenterol 2003 38 977 981 (Pubitemid 37455785)
34. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. Lam VW, Ng KK, Chok KS, Cheung TT, Yuen J, Tung H, Tso WK, Fan ST, Poon RT, J Am Coll Surg 2008 207 20 29
35. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Kagawa T, Koizumi J, Kojima S, Nagata N, Numata M, Watanabe N, Watanabe T, Mine T, Tokai RFA Study Group, Cancer 2010 116 3638 3644